Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)

  Measured over: Defined as the time from randomization to date of death from any cause, assessed up to 36 months after last patient inclusion

• Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR)

  Measured over: Assessed up to 36 months after last patient inclusion

• Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS)

  Measured over: Defined as the time from randomization to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months after last patient inclusion

• Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients

  Measured over: Assessed up to 36 months after last patient inclusion

Changes Tremor has spotted